靶向旁路补体途径的伊普可泮治疗IgA肾病:APPLAUSE-IgAN研究设计与依据
APPLAUSE-IgAN是一项多中心、随机、双盲、安慰剂对照、平行组3期研究,计划纳入约450例成人原发性IgA肾病且进展至肾衰竭高风险患者,在稳定最大耐受剂量ACEI或ARB基础上1:1随机接受伊普可泮200 mg或安慰剂每日两次治疗24个月,主要评估降低24小时UPCR和减缓eGFR下降的优效性。
要点
- 伊普可泮特异性结合因子B抑制旁路补体途径,2期研究显示可减少IgA肾病患者蛋白尿并减弱旁路途径激活。
- 研究计划纳入约450例活检确诊原发性IgA肾病且肾衰竭高风险成人,随机接受伊普可泮200 mg或安慰剂每日两次治疗24个月。
- 主要目标为中期分析时24小时UPCR降低及24个月总eGFR斜率减缓方面伊普可泮优于安慰剂。
核心结论
- APPLAUSE-IgAN将评估伊普可泮这一新型靶向治疗减少补体介导肾损伤、从而减缓或预防IgA肾病进展的获益与安全性。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照、平行组3期研究,计划纳入约450例活检确诊原发性IgA肾病且肾衰竭高风险成人(年龄≥18岁)。
- 在稳定且最大耐受剂量ACEI或ARB治疗基础上,按1:1随机接受伊普可泮200 mg或安慰剂每日两次,治疗24个月。
- 预设中期分析将在主研究人群约250例患者完成9个月访视时进行。
主要发现
- 2期研究显示伊普可泮减少IgA肾病患者蛋白尿并减弱旁路补体途径激活,支持其进入3期研究评估。
关键数值与推荐
- 主要目标之一为中期分析时证明伊普可泮在降低24小时尿蛋白肌酐比(UPCR)方面优于安慰剂。
- 主要目标之一为研究完成时证明伊普可泮在减缓24个月估算的总eGFR斜率方面优于安慰剂。
- 患者报告结局、安全性和耐受性作为次要结局评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Targeting the alternative complement pathway (AP) is an attractive therapeutic strategy because of its role in immunoglobulin A nephropathy (IgAN) pathophysiology. Iptacopan (LNP023), a proximal complement inhibitor that specifically binds to factor B and inhibits the AP, reduced proteinuria and attenuated AP activation in a Phase 2 study of patients with IgAN, thereby supporting the rationale for its evaluation in a Phase 3 study. METHODS: APPLAUSE-IgAN (NCT04578834) is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 study enrolling approximately 450 adult patients (aged ≥18 years) with biopsy-confirmed primary IgAN at high risk of progression to kidney failure despite optimal supportive treatment. Eligible patients receiving stable and maximally tolerated doses of angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs) will be randomized 1:1 to either iptacopan 200 mg or placebo twice daily for a 24-month treatment period. A prespecified interim analysis (IA) will be performed when approximately 250 patients from the main study population complete the 9-month visit. The primary objective is to demonstrate superiority of iptacopan over placebo in reducing 24-hour urine protein-to-creatinine ratio (UPCR) at the IA and demonstrate the superiority of iptacopan over placebo in slowing the rate of estimated glomerular filtration rate (eGFR) decline (total eGFR slope) estimated over 24 months at study completion. The effect of iptacopan on patient-reported outcomes, safety, and tolerability will be evaluated as secondary outcomes. CONCLUSIONS: APPLAUSE-IgAN will evaluate the benefits and safety of iptacopan, a novel targeted therapy for IgAN, in reducing complement-mediated kidney damage and thus slowing or preventing disease progression.
引用
- Rizk DV, Rovin BH, Zhang H, et al. Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study. Kidney Int Rep. 2023. PMID: 37180505. doi:10.1016/j.ekir.2023.01.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。